-
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
23 Apr 2024 11:30 GMT
… in the second half of … collaboration profitability, compared …
KINIKSA PHARMACEUTICALS, LTD.
CONSOLIDATED STATEMENTS OF OPERATIONS …
March 31,
2024
2023
Revenue:
Product revenue, net
$
78,885
$ …
-
Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts
22 Apr 2024 21:22 GMT
… April 19th, shares of Hookipa Pharma (NASDAQ:HOOK) closed at $0 … for HB-200 in the second half of this year. Clinical HOOK … initial costs, but bring in revenue perhaps 2 years faster? Equally … in 1L HBV16+ HNSCC (Hookup Pharma';s 03/24 …
-
Baron Health Care Fund Q1 2024 Shareholder Letter
23 Apr 2024 14:48 GMT
… operating margin expansion. Within pharmaceuticals, not owning certain … ), argenx, and Vertex Pharmaceuticals Incorporated (VRTX) also underperformed … better revenue growth. They may not be profitable today, … improving trends in the second half of 2024 and …
-
Danaher Corporation (DHR) Q1 2024 Earnings Call Transcript
23 Apr 2024 14:48 GMT
… and core revenue declined 4%. Geographically, core revenues in developed … remains challenging. Our gross profit margin for the first … in the second half of 2023. In developed markets, pharma and biotech … . But then in the second half, we should see some …
-
Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results
23 Apr 2024 14:48 GMT
… margins and increased long-term profits. Generics are also a … more promising products for the second half of the decade, and … generic competition. Full year revenue and operating income growth guidance … pure-play, high-margin pharma company with a strong …
-
Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?
18 Apr 2024 12:47 GMT
… its pipeline.
Biotech giant Vertex Pharmaceuticals (VRTX -0.27%) … past six months, the drugmaker has earned important regulatory approvals … for this candidate in the second half of the year.
Vertex … decade, Vertex's revenue and earnings continue moving in …
-
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
17 Apr 2024 21:38 GMT
… Life, a not-for-profit spinal cord injury research … Kelly brings three decades of pharmaceutical experience, playing instrumental roles … trial that commenced in the second half of 2023.
G… limitation, a lack of revenue, insufficient funding, the impact …
-
Research houses reiterate ‘overweight’ call on healthcare sector
23 Apr 2024 03:59 GMT
… to continue to grow while revenue intensity improves, driven by higher … , we see robust sales of pharmaceuticals and over-the-counter (OTC … , the pharmaceutical segment should see a robust recovery in the second half of …
-
SS Innovations International Announces Q1 2024 Company Updates
22 Apr 2024 12:00 GMT
Significant milestones achieved for SSi Mantra Made-in-India surgical robotic system
FORT LAUDERDALE, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative …
-
It's big news for these Texas towns.
22 Apr 2024 18:58 GMT
… expected to open in the second half of 2026 and will be … our business community. The tax revenue from this endeavor will benefit … grocery pick-up area and pharmacy drive-thru. A future H … exciting from a sales tax revenue point of view, but as …